CN117440829A - 用于治疗癌症的药物组合 - Google Patents

用于治疗癌症的药物组合 Download PDF

Info

Publication number
CN117440829A
CN117440829A CN202280036608.2A CN202280036608A CN117440829A CN 117440829 A CN117440829 A CN 117440829A CN 202280036608 A CN202280036608 A CN 202280036608A CN 117440829 A CN117440829 A CN 117440829A
Authority
CN
China
Prior art keywords
amino acid
protein
fragment
yope
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280036608.2A
Other languages
English (en)
Chinese (zh)
Inventor
S·伊泰格
C·卡斯帕
F·萨柏
M·阿姆斯特茨
M·杜瓦尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
T3 Pharmaceuticals AG
Original Assignee
T3 Pharmaceuticals AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T3 Pharmaceuticals AG filed Critical T3 Pharmaceuticals AG
Publication of CN117440829A publication Critical patent/CN117440829A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280036608.2A 2021-03-25 2022-03-24 用于治疗癌症的药物组合 Pending CN117440829A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21164882.9 2021-03-25
EP21164882 2021-03-25
PCT/EP2022/057752 WO2022200493A1 (fr) 2021-03-25 2022-03-24 Combinaisons pharmaceutiques pour le traitement du cancer

Publications (1)

Publication Number Publication Date
CN117440829A true CN117440829A (zh) 2024-01-23

Family

ID=75362326

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280036608.2A Pending CN117440829A (zh) 2021-03-25 2022-03-24 用于治疗癌症的药物组合

Country Status (14)

Country Link
US (1) US20240165265A1 (fr)
EP (1) EP4313310A1 (fr)
JP (1) JP2024511096A (fr)
KR (1) KR20230160895A (fr)
CN (1) CN117440829A (fr)
AU (1) AU2022244124A1 (fr)
BR (1) BR112023019473A2 (fr)
CA (1) CA3210774A1 (fr)
CL (1) CL2023002812A1 (fr)
CO (1) CO2023012667A2 (fr)
IL (1) IL305974A (fr)
MX (1) MX2023010989A (fr)
PE (1) PE20240636A1 (fr)
WO (1) WO2022200493A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002312778A1 (en) 2001-03-26 2002-10-08 Universite Catholique De Louvain Type iii bacterial strains for use in medicine
EP3331554B1 (fr) * 2015-08-03 2022-05-11 The U.S.A. as represented by the Secretary, Department of Health and Human Services Mutants de délétion de la protéine brachyury, vecteurs sans levure codant pour les mutants de délétion de la protéine brachyury, et leur utilisation
CN108884466B (zh) * 2015-11-19 2022-06-03 巴塞尔大学 基于细菌的蛋白递送
MY192537A (en) * 2016-12-20 2022-08-26 Univ Basel Virulence attenuated bacteria based protein delivery
US20200121739A1 (en) * 2017-01-18 2020-04-23 Evelo Biosciences, Inc. Bacteria for treating cancer

Also Published As

Publication number Publication date
PE20240636A1 (es) 2024-03-27
WO2022200493A1 (fr) 2022-09-29
JP2024511096A (ja) 2024-03-12
BR112023019473A2 (pt) 2023-12-05
AU2022244124A9 (en) 2023-11-16
CO2023012667A2 (es) 2023-09-29
CA3210774A1 (fr) 2022-09-29
MX2023010989A (es) 2023-09-27
EP4313310A1 (fr) 2024-02-07
IL305974A (en) 2023-11-01
CL2023002812A1 (es) 2024-04-05
AU2022244124A1 (en) 2023-11-09
KR20230160895A (ko) 2023-11-24
US20240165265A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
CN110325545B (zh) 基于减毒细菌的蛋白递送
Schnappinger et al. Tetracyclines: antibiotic action, uptake, and resistance mechanisms
CN110913875A (zh) 程序化以在肿瘤细胞中产生免疫调节子和抗癌治疗剂的微生物
CN111246865A (zh) 程序化以在肿瘤细胞中产生免疫调节剂和抗癌治疗剂的微生物
CN116802196A (zh) 基于细菌的蛋白质递送
CN117440829A (zh) 用于治疗癌症的药物组合
CN117425671A (zh) 用于治疗癌症的药物组合
US20080299617A1 (en) Methods and host cells for recombinant protein expression
EA044058B1 (ru) Доставка белков на основе бактерий, аттенуированных по вирулентности
US20210024975A1 (en) Methods for identifying inhibitors of lipid a deacylase and expression vectors related to same
Newns Analysis of a Fitness-Conferring Compensatory Mutation in the mleN Gene of Antibiotic-Resistant Neisseria gonorrhoeae and Development of a Potent and Gonococcal-Selective LpxC Inhibitor as a Potential Treatment for Gonorrhea
Hoffman The Role of the Transcriptional Antiterminator RfaH in Lipopolysaccharide Synthesis, Resistance to Antimicrobial Peptides, and Virulence of Yersinia Pseudotuberculosis and Yersinia Pestis
Charity Transcription regulation of virulence gene expression in Francisella tularensis
Collier et al. Investigation of the replication and the role of (p) ppGpp in the pathogen Brucella abortus
Rowley Characterisation of the S. Typhimurium σE regulon

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination